Humanigen to Present at Upcoming Investor Conferences
Humanigen, Inc. (Nasdaq: HGEN) announced participation in several virtual investor conferences focusing on COVID-19 therapeutics. Key events include:
- ROTH Capital Healthcare Event on October 28, 2020.
- Bryan, Garnier & Co European Healthcare Conference on November 16-17, 2020.
- Stifel Virtual Healthcare Conference on November 16-18, 2020.
- Jefferies London Healthcare Conference on November 17-19, 2020.
Live webcasts will be available on the Humanigen website, with archived presentations for 30 days post-event.
- None.
- None.
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate lenzilumab™, today announced that the Company’s management will present or participate in panel discussions at the following upcoming virtual investor conferences:
ROTH Capital Healthcare Event – COVID-19 Therapeutics in Development (October 28, 2020)
Date: Wednesday, October 28
Panel series: Immune Modulators to Ameliorate COVID Sequelae 2
Panel time: 9:00 AM ET
Registration link: https://roth.zoom.us/webinar/register/WN_FF_LgnOeQmm7VsRye97DtQ
Bryan, Garnier & Co European Healthcare Conference (November 16-17, 2020)
Date: Monday, November 16
For more information: https://www.bryangarnier.com/home/sectors/healthcare/
Stifel Virtual Healthcare Conference (November 16-18, 2020)
Date: Tuesday, November 17
Presentation time: 1:20 PM ET
Live webcast link: https://wsw.com/webcast/stifel27/hgen/2071712
Jefferies London Healthcare Conference (November 17-19, 2020)
Date: Thursday, November 19
Presentation time: 6:45 PM GMT (2:45 PM ET)
Live webcast link: https://wsw.com/webcast/jeff141/hgen/1826850
The conferences are being held in a virtual format. A live webcast of the presentation may be accessed on the Events section of the Humanigen website https://www.humanigen.com/events. Archived replay will be available on the Company website for 30 days following the event.
About Humanigen, Inc.
Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. The company’s immediate focus is to prevent or minimize the cytokine storm that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab™ as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab as sequenced therapy with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit www.humanigen.com.
Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability; our dependence on partners to further the development of our product candidates; the costs associated with CMC work and the uncertainties inherent in the development and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.
